An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Olema Pharmaceuticals, Inc. announces CEO participation in a panel on Breast Cancer at the 2024 CG Horizons in Oncology Virtual Conference. The company focuses on developing targeted therapies for women's cancers.
Positive
None.
Negative
None.
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.
About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact: Geoffrey Mogilner, Vice President, Investor Relations and Communications ir@olema.com
FAQ
What event will Sean P. Bohen participate in?
Sean P. Bohen will participate in a panel on 'Breast Cancer – Shifting an Entrenched Paradigm' at the 2024 CG Horizons in Oncology Virtual Conference.
What is the focus of Olema Pharmaceuticals, Inc.?
Olema Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of targeted therapies for women's cancers.
When will the panel take place?
The panel will take place on Monday, April 15, 2024, at 2:00 p.m. ET.
olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.